Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours
Open Access
- 19 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drugs in R&D
- Vol. 21 (1), 103-111
- https://doi.org/10.1007/s40268-020-00336-x
Abstract
Introduction ModraDoc006 is a novel docetaxel tablet formulation that is co-administrated with the cytochrome P450 3A4 and P-glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Objectives This study evaluated the effect of food consumed prior to administration of ModraDoc006/r on the pharmacokinetics of docetaxel and ritonavir. Methods Patients with advanced solid tumours were enrolled in this randomized crossover study to receive ModraDoc006/r in a fasted state in week 1 and after a standardized high-fat meal in week 2 and vice versa. Pharmacokinetic sampling was conducted until 48 h after both study drug administrations. Docetaxel and ritonavir plasma concentrations were determined using liquid chromatography with tandem mass spectrometry. Safety was evaluated with the Common Terminology Criteria for Adverse Events, version 4.03. Results In total, 16 patients completed the food-effect study. The geometric mean ratio (GMR) for the docetaxel area under the plasma concentration–time curve (AUC)0–48, AUC0–inf and maximum concentration (Cmax) were 1.11 (90% confidence interval [CI] 0.93–1.33), 1.19 (90% CI 1.00–1.41) and 1.07 (90% CI 0.81–1.42) in fed versus fasted conditions, respectively. For the ritonavir Cmax, the GMR was 0.79 (90% CI 0.69–0.90), whereas the AUC0–48 and AUC0–inf were bioequivalent. The most frequent treatment-related toxicities were grade ≤ 2 diarrhoea and fatigue. Hypokalaemia was the only observed treatment-related grade 3 toxicity. Conclusions The docetaxel and ritonavir exposure were not bioequivalent, as consumption of a high-fat meal prior to administration of ModraDoc006/r resulted in a slightly higher docetaxel exposure and lower ritonavir Cmax. Since docetaxel exposure is the only clinically relevant parameter in our patient population, the overall conclusion is that combined ModraDoc006 and ritonavir treatment may be slightly affected by concomitant intake of a high-fat meal. In view of the small effect, it is most likely that the intake of a light meal will not affect the systemic exposure to docetaxel. ClinicalTrials.gov Identifier NCT03147378, date of registration: May 10 2017.Keywords
Funding Information
- Modra Pharmaceuticals BV
This publication has 30 references indexed in Scilit:
- Anticancer oral therapy: Emerging related issuesCancer Treatment Reviews, 2010
- Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid TumorsClinical Cancer Research, 2009
- Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLCLung Cancer, 2008
- Effect of Food on the Pharmacokinetic Behavior of the Potent Oral Taxane BMS-275183Clinical Cancer Research, 2008
- The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjectsJournal of the International AIDS Society, 2008
- Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS systemThe European Journal of Health Economics, 2007
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerThe New England Journal of Medicine, 2004
- Answering Patients' Needs: Oral Alternatives to Intravenous TherapyThe Oncologist, 2001
- RitonavirClinical Pharmacokinetics, 1998
- A study of quality of life in cancer patients receiving palliative chemotherapySocial Science & Medicine (1982), 1992